ATPS-19POLO LIKE KINASE INHIBITOR VOLASERTIB SYNERGISTICALLY IMPROVE RADIATION EFFICACY IN GLIOBLASTOMA
نویسندگان
چکیده
منابع مشابه
The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells
Background Despite the availability of hundreds of cancer drugs, there is insufficient data on the efficacy of these drugs on the extremely heterogeneous tumor cell populations of glioblastoma (GBM). Results The PKIS of 357 compounds was initially evaluated in 15 different GSC lines which then led to a more focused screening of the 21 most highly active compounds in 11 unique GSC lines using ...
متن کاملPolo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas
Survival following anthracycline-based chemotherapy remains poor among patients with most T-cell lymphoproliferative disorders. This may be attributed, at least in part, to cell-autonomous mechanisms of chemotherapy resistance observed in these lymphomas, including the loss of important tumor suppressors and the activation of signaling cascades that culminate in the expression and activation of...
متن کاملVolasertib (BI 6727), a novel polo-like kinase inhibitor, reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cells
Introduction Volasertib (BI 6727) is a highly potent molecular targeted anticancer agent that induces mitotic arrest and apoptosis by selectively targeting the Polo-like kinase (PLK) family of proteins [1]. It is currently in early clinical development against various human tumors. PLK1 is the best characterized member of the PLK family and is recognized to play essential roles in the regulatio...
متن کاملPhase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia
This phase I trial conducted in Japanese patients with acute myeloid leukemia evaluated the safety, maximum tolerated dose and pharmacokinetics of volasertib (BI 6727), a selective Polo-like kinase inhibitor. The primary endpoints were the maximum tolerated dose of volasertib and the incidence of dose-limiting toxicities. Secondary endpoints were best response and remission duration. Other endp...
متن کاملPolo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia
Acute myeloid leukemia (AML) is the second most common type of leukemia in adults. Incidence of AML increases with age with a peak incidence at 67 years. Patients older than 60 years have an unfavorable prognosis due to resistance to conventional chemotherapy. Volasertib (BI 6727) is a cell-cycle regulator targeting polo-like kinase which has been evaluated in clinical trials in AML. We evaluat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-Oncology
سال: 2015
ISSN: 1522-8517,1523-5866
DOI: 10.1093/neuonc/nov204.19